{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:40:35Z","timestamp":1761946835322,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP16K09568"],"award-info":[{"award-number":["JP16K09568"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00280-020-04034-y","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T18:03:05Z","timestamp":1581357785000},"page":"605-614","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity"],"prefix":"10.1007","volume":"85","author":[{"given":"Takahisa","family":"Kawamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiyo K.","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Kenmotsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuhiko","family":"Taira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Omori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhisa","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushige","family":"Wakuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tateaki","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruyasu","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taisei","family":"Mushiroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Tanigawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,10]]},"reference":[{"issue":"1","key":"4034_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.20138","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62(1):10\u201329. https:\/\/doi.org\/10.3322\/caac.20138","journal-title":"CA Cancer J Clin"},{"issue":"25","key":"4034_CR2","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380\u20132388","journal-title":"N Engl J Med"},{"issue":"2","key":"4034_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M; West Japan Oncology Group","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M; West Japan Oncology Group (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121\u2013128. https:\/\/doi.org\/10.1016\/S1470-2045(09)70364-X","journal-title":"Lancet Oncol"},{"issue":"8","key":"4034_CR4","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1097\/JTO.0b013e31821d43a8","volume":"6","author":"H Satoh","year":"2011","unstructured":"Satoh H, Inoue A, Kobayashi K, Maemondo M, Oizumi S, Isobe H, Gemma A, Saijo Y, Yoshizawa H, Hagiwara K, Nukiwa T (2011) Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations. J Thorac Oncol 6(8):1413\u20131417. https:\/\/doi.org\/10.1097\/JTO.0b013e31821d43a8","journal-title":"J Thorac Oncol"},{"issue":"12","key":"4034_CR5","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","volume":"21","author":"M Fukuoka","year":"2003","unstructured":"Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21(12):2237\u20132246. https:\/\/doi.org\/10.1200\/JCO.2003.10.038","journal-title":"J Clin Oncol"},{"issue":"9","key":"4034_CR6","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1200\/JCO.2002.10.112","volume":"20","author":"M Ranson","year":"2002","unstructured":"Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H, Rowinsky EK (2002) ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20(9):2240\u20132250. https:\/\/doi.org\/10.1200\/JCO.2002.10.112","journal-title":"J Clin Oncol"},{"issue":"6","key":"4034_CR7","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/annonc\/mdg250","volume":"14","author":"K Nakagawa","year":"2003","unstructured":"Nakagawa K, Tamura T, Negoro S, Kudoh S, Yamamoto N, Yamamoto N, Takeda K, Swaisland H, Nakatani I, Hirose M, Dong RP, Fukuoka M (2003) Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 14(6):922\u2013930. https:\/\/doi.org\/10.1093\/annonc\/mdg250","journal-title":"Ann Oncol"},{"issue":"4","key":"4034_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10637-006-5269-2","volume":"24","author":"J Li","year":"2006","unstructured":"Li J, Brahmer J, Messersmith W, Hidalgo M, Baker SD (2006) Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. Invest New Drugs 24(4):291\u2013297. https:\/\/doi.org\/10.1007\/s10637-006-5269-2","journal-title":"Invest New Drugs"},{"issue":"11\u201312","key":"4034_CR9","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cca.2011.02.023","volume":"412","author":"S Bouchet","year":"2011","unstructured":"Bouchet S, Chauzit E, Ducint D, Castaing N, Canal-Raffin M, Moore N, Titier K, Molimard M (2011) Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC\/MS-MS. Clin Chim Acta 412(11\u201312):1060\u20131067. https:\/\/doi.org\/10.1016\/j.cca.2011.02.023","journal-title":"Clin Chim Acta"},{"key":"4034_CR10","unstructured":"Validation. Rockville, Food and Drug Administration (2001) Guidance for Industry: Bioanalytical Method US Department of Health and Human Services. FDA, Center for Drug Evaluation and Research"},{"issue":"8","key":"4034_CR11","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1002\/jps.24064","volume":"103","author":"K Vanstraelen","year":"2014","unstructured":"Vanstraelen K, Wauters J, De Loor H, Vercammen I, Annaert P, Lagrou K, Spriet I (2014) Protein-binding characteristics of voriconazole determined by high-throughput equilibrium dialysis. J Pharm Sci 103(8):2565\u20132570. https:\/\/doi.org\/10.1002\/jps.24064","journal-title":"J Pharm Sci"},{"key":"4034_CR12","unstructured":"NCI, Common Terminology Criteria for Adverse Events Version 4.0. NCI, NIH, DHHS. 2009. Available at https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 29 May 2009"},{"issue":"2","key":"4034_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"1","key":"4034_CR14","first-page":"1","volume":"40","author":"JM Kremer","year":"1988","unstructured":"Kremer JM, Wilting J, Janssen LH (1988) Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 40(1):1\u201347","journal-title":"Pharmacol Rev"},{"issue":"10","key":"4034_CR15","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/sj.bjc.6604355","volume":"98","author":"N Widmer","year":"2008","unstructured":"Widmer N, Decosterd LA, Leyvraz S, Duchosal MA, Rosselet A, Debiec-Rychter M, Csajka C, Biollaz J, Buclin T (2008) Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer 98(10):1633\u20131640. https:\/\/doi.org\/10.1038\/sj.bjc.6604355","journal-title":"Br J Cancer"},{"issue":"11","key":"4034_CR16","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1111\/bcp.13354","volume":"83","author":"H Kenmotsu","year":"2017","unstructured":"Kenmotsu H, Imamura CK, Ono A, Omori S, Nakashima K, Wakuda K, Taira T, Naito T, Murakami H, Takahashi T, Tanigawara Y (2017) The effects of advanced age and serum alpha1 -acid glycoprotein on docetaxel unbound exposure and dose-limiting toxicity in cancer patients. Br J Clin Pharmacol 83(11):2416\u20132425. https:\/\/doi.org\/10.1111\/bcp.13354","journal-title":"Br J Clin Pharmacol"},{"key":"4034_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03788-4","author":"T Kawata","year":"2019","unstructured":"Kawata T, Higashimori M, Itoh Y, Tomkinson H, Johnson MG, Tang W, Nyberg F, Jiang H, Tanigawara Y (2019) Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer. Cancer Chemother Pharmacol. https:\/\/doi.org\/10.1007\/s00280-019-03788-4","journal-title":"Cancer Chemother Pharmacol"},{"issue":"23","key":"4034_CR18","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1093\/jnci\/djj466","volume":"98","author":"J Li","year":"2006","unstructured":"Li J, Karlsson MO, Brahmer J, Spitz A, Zhao M, Hidalgo M, Baker SD (2006) CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst 98(23):1714\u20131723. https:\/\/doi.org\/10.1093\/jnci\/djj466","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"4034_CR19","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/jnci\/djj469","volume":"98","author":"G Cusatis","year":"2006","unstructured":"Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, Baker SD (2006) Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 98(23):1739\u20131742. https:\/\/doi.org\/10.1093\/jnci\/djj469","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"4034_CR20","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.2010.31.3197","volume":"29","author":"CF Spraggs","year":"2011","unstructured":"Spraggs CF, Budde LR, Briley LP, Bing N, Cox CJ, King KS, Whittaker JC, Mooser VE, Preston AJ, Stein SH, Cardon LR (2011) HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 29(6):667\u2013673. https:\/\/doi.org\/10.1200\/JCO.2010.31.3197","journal-title":"J Clin Oncol"},{"issue":"6","key":"4034_CR21","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1158\/1078-0432.CCR-15-2044","volume":"22","author":"CF Xu","year":"2016","unstructured":"Xu CF, Johnson T, Wang X, Carpenter C, Graves AP, Warren L, Xue Z, King KS, Fraser DJ, Stinnett S, Briley LP, Mitrica I, Spraggs CF, Nelson MR, Tada H, du Bois A, Powles T, Kaplowitz N, Pandite LN (2016) HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer. Clin Cancer Res 22(6):1371\u20131377. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2044","journal-title":"Clin Cancer Res"},{"issue":"21","key":"4034_CR22","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129\u20132139. https:\/\/doi.org\/10.1056\/NEJMoa040938","journal-title":"N Engl J Med"},{"issue":"16","key":"4034_CR23","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","volume":"290","author":"MG Kris","year":"2003","unstructured":"Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290(16):2149\u20132158. https:\/\/doi.org\/10.1001\/jama.290.16.2149","journal-title":"JAMA"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04034-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-020-04034-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04034-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:53:36Z","timestamp":1612918416000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-020-04034-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,10]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["4034"],"URL":"https:\/\/doi.org\/10.1007\/s00280-020-04034-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2020,2,10]]},"assertion":[{"value":"24 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Chiyo K. Imamura, Hirotsugu Kenmotsu, Shota Omori, Kazushige Wakuda, Haruyasu Murakami, Toshiaki Takahashi, and Yusuke Tanigawara have received honouraria from AstraZeneca. Kazushige Wakuda, Hirotsugu Kenmotsu, and Toshiaki Takahashi have received a grant from AstraZeneca. For the remaining authors, no conflicts of interest are declared. All of the conflicts of interest are outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}